Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China
Avalon GloboCare (NASDAQ: ALBT) has secured a patent in China for its CAR-T and CAR-NK cell technology, valid for 20 years from April 4, 2025. The patent, titled 'Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same,' was granted by the China National Intellectual Property Administration under No. CN 114502188 B.
Co-developed with Hong Kong-based Arbele , the technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to reduce tumor escape risk, and a localized cytokine induction mechanism to enhance CAR cell performance. The patent complements existing protections in the U.S. and other PCT territories, strengthening Avalon's global intellectual property portfolio in cell-based immunotherapy.
Avalon GloboCare (NASDAQ: ALBT) ha ottenuto un brevetto in Cina per la sua tecnologia CAR-T e CAR-NK, valido per 20 anni a partire dal 4 aprile 2025. Il brevetto, intitolato 'Recettore Chimerico dell'Antigene con Immunosorveglianza Artificiale e Cellule che Espressano lo Stesso,' è stato concesso dall'Amministrazione Nazionale della Proprietà Intellettuale della Cina con il numero CN 114502188 B.
Sviluppata in collaborazione con Arbele, con sede a Hong Kong, la tecnologia presenta un design bispecifico Anti-CD19xCD22 CAR che mira a entrambi gli antigeni CD19 e CD22 per ridurre il rischio di fuga tumorale, e un meccanismo di induzione di citochine localizzato per migliorare le prestazioni delle cellule CAR. Il brevetto si aggiunge alle protezioni esistenti negli Stati Uniti e in altri territori PCT, rafforzando il portafoglio globale di proprietà intellettuale di Avalon nell'immunoterapia basata su cellule.
Avalon GloboCare (NASDAQ: ALBT) ha obtenido una patente en China para su tecnología de células CAR-T y CAR-NK, válida por 20 años a partir del 4 de abril de 2025. La patente, titulada 'Receptor Quimérico de Antígeno con Inmunovigilancia Artificial y Células que Expresan lo Mismo,' fue concedida por la Administración Nacional de Propiedad Intelectual de China bajo el número CN 114502188 B.
Co-desarrollada con Arbele, con sede en Hong Kong, la tecnología presenta un diseño bispecífico Anti-CD19xCD22 CAR que apunta a los antígenos CD19 y CD22 para reducir el riesgo de escape tumoral, y un mecanismo de inducción de citoquinas localizado para mejorar el rendimiento de las células CAR. La patente complementa las protecciones existentes en EE. UU. y otros territorios del PCT, fortaleciendo el portafolio global de propiedad intelectual de Avalon en inmunoterapia basada en células.
아발론 글로보케어 (NASDAQ: ALBT)는 CAR-T 및 CAR-NK 세포 기술에 대한 특허를 중국에서 확보하였으며, 이는 2025년 4월 4일부터 20년간 유효합니다. 이 특허는 '인공 면역 감시 키메라 항원 수용체 및 이를 발현하는 세포'라는 제목으로, 중국 국가 지식 재산권 관리국에 의해 CN 114502188 B 번호로 승인되었습니다.
홍콩에 본사를 둔 Arbele와 공동 개발된 이 기술은 CD19 및 CD22 항원을 모두 겨냥하여 종양 탈출 위험을 줄이는 이중 특이성 Anti-CD19xCD22 CAR 설계를 특징으로 하며, CAR 세포 성능을 향상시키기 위한 국소화된 사이토카인 유도 메커니즘을 포함합니다. 이 특허는 미국 및 기타 PCT 지역의 기존 보호 조치를 보완하여 아발론의 세포 기반 면역 요법에 대한 글로벌 지식 재산 포트폴리오를 강화합니다.
Avalon GloboCare (NASDAQ: ALBT) a obtenu un brevet en Chine pour sa technologie de cellules CAR-T et CAR-NK, valable pendant 20 ans à partir du 4 avril 2025. Le brevet, intitulé 'Récepteur Antigénique Chimérique à Surveillance Immunitaire Artificielle et Cellules Exprimant le Même,' a été accordé par l'Administration Nationale de la Propriété Intellectuelle de Chine sous le numéro CN 114502188 B.
Co-développée avec Arbele, basée à Hong Kong, la technologie présente un design bispecifique Anti-CD19xCD22 CAR ciblant à la fois les antigènes CD19 et CD22 afin de réduire le risque d'évasion tumorale, ainsi qu'un mécanisme d'induction de cytokines localisé pour améliorer les performances des cellules CAR. Le brevet complète les protections existantes aux États-Unis et dans d'autres territoires PCT, renforçant le portefeuille mondial de propriété intellectuelle d'Avalon dans l'immunothérapie basée sur les cellules.
Avalon GloboCare (NASDAQ: ALBT) hat ein Patent in China für seine CAR-T- und CAR-NK-Zelltechnologie gesichert, das ab dem 4. April 2025 für 20 Jahre gültig ist. Das Patent mit dem Titel 'Künstliche Immunüberwachungs-Chimäre Antigenrezeptoren und Zellen, die dasselbe exprimieren,' wurde von der Nationalen Verwaltung für geistiges Eigentum Chinas unter der Nummer CN 114502188 B erteilt.
In Zusammenarbeit mit dem in Hongkong ansässigen Unternehmen Arbele entwickelt, verfügt die Technologie über ein bispezifisches Anti-CD19xCD22 CAR-Design, das sowohl CD19- als auch CD22-Antigene angreift, um das Risiko einer Tumorfreiheit zu reduzieren, sowie einen lokalisierten Zytokininduktionsmechanismus zur Verbesserung der CAR-Zellleistung. Das Patent ergänzt bestehende Schutzmaßnahmen in den USA und anderen PCT-Gebieten und stärkt Avalons globales geistiges Eigentumsportfolio im Bereich der zellbasierten Immuntherapie.
- Secured 20-year patent protection in China for CAR-T technology
- Technology already protected in U.S. and other PCT territories
- Expanded global intellectual property portfolio in cell-based immunotherapy
- None.
Insights
Avalon GloboCare's patent issuance in China represents a strategic expansion of its intellectual property portfolio for CAR-T and CAR-NK cell technology. The 20-year protection period is particularly significant as it secures Avalon's position in this specialized field through 2045 in a major global market.
The technology addresses two critical limitations in current immunotherapies. First, the bispecific Anti-CD19xCD22 CAR design targets multiple tumor markers simultaneously, potentially reducing the common problem of antigen escape where cancer cells evade treatment by downregulating specific antigens. Second, the localized cytokine induction mechanism aims to improve efficacy while potentially reducing systemic toxicity issues that plague many current CAR-T therapies.
However, investors should understand that this patent represents intellectual property protection rather than immediate commercial value. The path from patent to marketable therapy typically involves years of clinical development, regulatory approvals, and manufacturing scale-up. The announcement lacks details on the development stage of this technology or timelines for potential commercialization.
While strengthening Avalon's competitive positioning in the rapidly evolving cell therapy landscape, the patent itself doesn't guarantee clinical or commercial success. Its true value will ultimately depend on the company's ability to translate this protected intellectual property into viable therapeutic products or licensing opportunities in a highly competitive field.
This patent issuance significantly enhances Avalon's intellectual asset portfolio by securing protection in China—a strategically important market with growing cell therapy development activities. The patent's 20-year exclusivity window provides Avalon substantial runway to commercialize or license this technology in what's becoming one of the world's largest healthcare markets.
The comprehensive global protection strategy—with patents already secured in the US and through PCT mechanisms in other territories—demonstrates sophisticated IP management. This multi-jurisdiction approach creates potential value through either direct commercialization or through licensing/partnership opportunities across different markets.
The technology's dual-targeting mechanism and localized cytokine activation represent innovations that appear defensible from an IP perspective, potentially creating barriers to competitors. However, the cell therapy space is crowded with overlapping patents, and the actual enforceability and commercial freedom-to-operate would require deeper patent landscape analysis.
While valuable from an IP standpoint, patents in biotechnology face unique commercialization challenges. The technical complexity, regulatory hurdles, and significant capital requirements for bringing cell therapies to market mean that patent protection alone doesn't guarantee commercial success. The company will need to demonstrate not just innovation but clinical validity and marketability to transform this intellectual property into tangible shareholder value.
FREEHOLD, N.J., April 10, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration (CNIPA). The patent, entitled “Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same” and filed under application number CN2020800152050 and issued as No. CN 114502188 B, marks a milestone in the Company’s global intellectual property strategy. The patent term extends 20 years from the issuance date, effective April 4, 2025, and reflects Avalon’s continued commitment to pioneering immunotherapy technologies for global markets.
This patent, co-developed with Hong Kong-based Arbele Limited, represents an advancement in chimeric antigen receptor (CAR)-based therapies and broadens Avalon’s intellectual property portfolio. Already protected in the U.S. and other territories under the Patent Cooperation Treaty (PCT), this newly issued Chinese patent further reinforces Avalon’s intellectual property position in the global market.
The patent covers innovative technology designed to enhance the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells. Key features of the patent include:
- Bispecific Anti-CD19xCD22 CAR: A novel design that targets both CD19 and CD22 antigens for purposes of reducing the risk of tumor escape due to antigen loss.
- Localized Cytokine Induction: A mechanism that triggers cytokine responses only at the site of tumor engagement, for purposes of improving CAR cell cytotoxicity, survival, and proliferation, while also activating the patient’s own anti-tumor immune response.
“The official issuance of this patent in China not only expands our global intellectual property footprint but also strengthens our position in cell-based immunotherapy,” said David Jin, M.D., Ph.D., Avalon’s CEO. “"With 20 years of protection secured through this recent patent grant, we continue to demonstrate our commitment to advancing intellectual property that supports innovative cancer treatments.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the company owns and operates commercial real estate. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAir and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is the duration and scope of ALBT's new Chinese patent for CAR-T technology?
What are the key features of Avalon GloboCare's newly patented CAR-T technology?
Who did ALBT collaborate with to develop this patented CAR-T technology?
In which territories does ALBT now hold patents for their CAR-T technology?
